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Tuesday, March 8, 2011 429ahyperpolarization, is decreased with increased extracellular potassium, similar
to the effect of extracellular potassium on block of WT HERG by quinidine. In
addition, block of D540K by bepridil at120 mV, a voltage at which D540K is
open and does not inactivate is similar in 0 mM extracellular K and 20 mM
NH4 and reduced in 20 mM extracellular K and 20 mM extracellular Cs. Given
that the permeability sequence through HERG is PK>PCs>PNH4, these results
suggest that the permeant ion is not able to destabilize a trapped drug but is able
to destabilize a drug that is not trapped and suggest a possible role for the ac-
tivation gate in determining the extracellular potassium dependency of block of
HERG by certain compounds.
1 Barrows et al. (2009) Channels: 3(4) :239 248.
2 Stork et al. (2007) BJP151:1368-1376.
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Ion channel modulation is a major target for cardiovascular therapeutics. The
hERG-encoded Kþ current, IKr is essential for cardiac repolarization but also
a source of cardiotoxicity. Unintended hERG inhibition by diverse pharmaceu-
ticals can cause sudden cardiac death. We used a high-throughput assay to test
the hypothesis that IKr reduction in response to an inhibitor, dofetilide, could be
prevented by a small molecule. We screened more than 300,000 compounds for
agents that increase the IC70 of dofetilide.
One compound (VU0405601), with the desired activity was further character-
ized: On its own, VU0405601 enhances hERG test-pulse (10 mV) and tail cur-
rent (50 mV) 5.3 and 2.5 fold, respectively, with an EC50 around 22 mM.
VU0405601 shifted the half-maximal voltage-dependence (V1/2) of activation
by14mV. The activation time course was accelerated (899.7 vs 258.2 ms); ki-
netics of deactivation were slowed. The V1/2 of inactivation was shifted byþ16
mV. Rate of inactivation and recovery from inactivation were slowed and has-
tened, respectively. Studieswith the inactivation-removed hERG-S631Avariant
showed a greatly reducedVU0405601 effect on the test-pulse current, indicating
that reduced inactivation is the primary mechanism. Competition studies with
the hERG toxin BeKm-1 (binds the outer vestibule) and dofetilide (an inner cav-
ity blocker), revealed that BeKm-1 but not dofetilide suppressedVU0405601 ac-
tivator effects. Hence, VU0405601 impacts the outer vestibule.
Dofetilide block of IKr develops gradually, with continuous pulsing. After 15
minutes of pulsing, 89% of the current is inhibited with 100 nM dofetilide alone
but in the presence of VU0405601, 49% of the current remains, indicating that
VU0405601 protects hERG from inhibition. Development of a small molecule
that decreases the risk of arrhythmias in response to hERG inhibitors would im-
prove public health and facilitate drug discovery.
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The class Ia antiarrhythmic drug disopyramide (DISO) delays cardiac ventric-
ular repolarization through inhibition of the hERG-encoded, pore-forming sub-
unit of the rapid delayed rectifier Kþ current (IKr). In contrast with high-affinity
hERG blockers DISO’s inhibitory action on hERG is less dependent upon chan-
nel inactivation, raising the possibility that DISO binding to hERGmay in some
way be distinct [1,2]. Here the sensitivity to DISO of mutants of two aromatic
residues (Y652A and F656A) in the S6 domain was investigated. Whole-cell
patch clamp recordings were made at 37oC from HEK-293 cells stably express-
ing WT hERG or hERG mutants Y652A or F656A. WT hERG current (IhERG)
tails at 40 mV following depolarization to þ20 mV were inhibited with an
IC50 of 7.25 0.06 mM. The Y652A mutation greatly attenuated DISO inhibi-
tion of IhERG tail (IC50=402 5 0.04 mM) and also abolished voltage-
dependence of inhibition that was present for WT IhERG. F656A IhERG tails at
120 mV (recorded with a high [Kþ]e of 94 mM to facilitate current measure-
ment) yielded a very high IC50of 1.8550.07 mM. Preliminary docking anal-
ysis using a homology model built onto the KvAP crystal structure template
suggests that in low-energy binding configurations the aromatic groups of
DISO may reside at the lower end of the pore cavity. Collectively, these find-
ings suggest a critical role for canonical binding residues Y652 and F656 in
DISO inhibition of hERG and implicate Y652 in the voltage-dependence of
hERG inhibition by DISO.
This work was supported by the British Heart Foundation.
1. Paul AA et al (2001) BBRC, 280; 1243-50
2. McPate MJ et al (2008) Br J Pharmacol, 155, 957-662323-Pos Board B309
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Lyubov I. Brueggemann, Kenneth L. Byron.
KCNQ4 and KCNQ5 potassium channel subunits are expressed in vascular
smooth muscle cells, though it remains uncertain how these subunits assemble
to form functional channels. Using patch-clamp techniques, we compared the
electrophysiological characteristics and effects of diclofenac, a known KCNQ
channel activator, on human KCNQ4 and KCNQ5 channels expressed indi-
vidually or together in A7r5 rat aortic smooth muscle cells. The conductance
curves of the overexpressed channels were fit by a single Boltzmann function
in each case (V0.5 values: 31 mV, 44 mV, and 38 mV for KCNQ4,
KCNQ5, and KCNQ4/5, respectively). Diclofenac (100 mM) increased maxi-
mum conductance of KCNQ4 channels by 38%, but inhibited KCNQ5 and
KCNQ4/5 channels, reducing maximum conductance by 53% and by 32% re-
spectively. Differences in deactivation rates and distinct voltage-dependent ef-
fects of diclofenac on channel activation and deactivation observed with each
of the subunit combinations (KCNQ4, KCNQ5 and KCNQ4/5) were used as
diagnostic tools to evaluate native KCNQ currents in vascular smooth muscle
cells. A7r5 cells express only KCNQ5 channels endogenously and their re-
sponses to diclofenac closely resembled those of the overexpressed KCNQ5
currents. In contrast, mesenteric artery myocytes, which express both
KCNQ4 and KCNQ5 channels, displayed whole-cell KCNQ currents with
properties and diclofenac responses characteristic of overexpressed hetero-
meric KCNQ4/5 channels.2324-Pos Board B310
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Celecoxib is a COX-2 inhibitor that has been related to an increased car-
diovascular risk and that exerts several actions on different targets. The
aim of this study was to analyze the effects of this drug on human cardiac
voltage-gated potassium channels (Kv) involved on cardiac repolarization
Kv1.5 (IKur), Kv4.3þKChIP2 (Ito1) and Kv7.1þKCNE1 (IKs) and to com-
pare with another COX-2 inhibitor, rofecoxib. Currents were recorded in
transfected mammalian cells by whole-cell patch-clamp. Celecoxib blocked
all the Kv channels analyzed and rofecoxib was always less potent, except
on Kv4.3þKChIP2 channels. Kv1.5 block increased in the voltage range
of channel activation, decreasing at potentials positive to 0 mV. The
drug modified the activation curve of the channels that became biphasic.
Block was frequency-dependent, increasing at fastest frequencies. Cele-
coxib effects were not altered by TEAout in R487Y mutant Kv1.5 channels
but the kinetics of block were slower and the degree of block smaller with
TEAin, indicating that celecoxib acts from the cytosolic side. We con-
firmed the blocking properties of celecoxib on native Kv currents from
rat vascular cells, where Kv1.5 are the main contributors (IC50z7 mM).
Finally, we demonstrate that celecoxib prolongs the action potential dura-
tion in mouse cardiac myocytes and shortens it in guinea pig cardiac my-
ocytes; suggesting that Kv block induced by celecoxib may be of clinical
relevance. Supported by SAF2007-65868, SAF2008-03948, SAF2010-
14916, AGL2007-66108, RECAVA RD06/0014/0006 and Fundacio´n Mutua
Madrilen˜a.2325-Pos Board B311
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Celecoxib selectively inhibits COX-2, an inflammation-inducible cyclooxyge-
nase isoform. Recently it has been described that celecoxib produces secondary
effects because it affects the activity of several types of ion channels. Herein it
is reported that at therapeutically relevant concentrations celecoxib interacts
with Shab Kþ channels only inducing fast inactivation gating without blocking
the pore or significantly affecting other gating processes. This induced-
inactivation in turn causes a reduction of the size of IK. Also it was found
that a promoted fast inactivation that develops from both open and closed states
takes place when at least two celecoxib molecules bind to each channel. Our
results show for the first time that in addition to its intended therapeutic target
celecoxib is a unique tool to further study the mechanism of Shab channel
inactivation.
